ArticleNature communications2019
Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- ATG4B is required for mTORC1-mediated anabolic activity and is associated with clinical outcomes in non-small cell lung cancer.FEBS open bio · 2026Article
- Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.NPJ precision oncology · 2025Article
- The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity.International journal of molecular sciences · 2025Review
- Global profiling of alternative splicing in non-small cell lung cancer reveals novel histological and population differences.Oncogene · 2025Article
- Gene expression-based modeling of overall survival in Black or African American patients with lung adenocarcinoma.Frontiers in immunology · 2024Article
- Article
- Article
- Pre-diagnostic circulating p53 autoantibodies and subsequent lung cancer risk in low-income African and European Americans.Cancer epidemiology · 2022Article
- Oncogenic alterations reveal key strategies for precision oncology in melanoma treatment.Annals of translational medicine · 2022Article
- Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma.JAMA network open · 2022Article
- Immune response and inflammation in cancer health disparities.Trends in cancer · 2022Review
- Racial Disparities in Cigarette Smoking Behaviors and Differences Stratified by Metropolitan Area of Residence.International journal of environmental research and public health · 2022Article
- Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.Cancer medicine · 2022Article
- Racial disparities in the genetic landscape of lung cancer.Cancer health disparities · 2022Article
- Pan-cancer analyses of classical protein tyrosine phosphatases and phosphatase-targeted therapy in cancer.Frontiers in immunology · 2022Article
- JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.Carcinogenesis · 2021Article
- Review
- An overview of cancer health disparities: new approaches and insights and why they matter.Carcinogenesis · 2021Review
- Association ofFrontiers in oncology · 2021Article
- Cancer health disparities in racial/ethnic minorities in the United States.British journal of cancer · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 5 institutions in 1 country.
Funding
Abstract
Reducing or eliminating persistent disparities in lung cancer incidence and survival has been challenging because our current understanding of lung cancer biology is derived primarily from populations of European descent. Here we show results from a targeted sequencing panel using NCI-MD Case Control Study patient samples and reveal a significantly higher prevalence of PTPRT and JAK2 mutations in lung adenocarcinomas among African Americans compared with European Americans. This increase in mutation frequency was validated with independent WES data from the NCI-MD Case Control Study and TCGA. We find that patients carrying these mutations have a concomitant increase in IL-6/STAT3 signaling and miR-21 expression. Together, these findings suggest the identification of these potentially actionable mutations could have clinical significance for targeted therapy and the enrollment of minority populations in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.